New injection shows promise for Tough-to-Treat skin cancer
Disease control
Completed
This study tested whether injecting a new drug called BO-112 directly into tumors, along with the standard immunotherapy pembrolizumab, could help patients with advanced melanoma whose cancer had stopped responding to previous immunotherapy. The trial involved 42 adults with stag…
Phase: PHASE2 • Sponsor: Highlight Therapeutics • Aim: Disease control
Last updated Mar 12, 2026 13:51 UTC